BrightGene Bio Medical Technology C (688166) - Cash Flow Conversion Efficiency

Latest as of June 2023: 0.011x

Based on the latest financial reports, BrightGene Bio Medical Technology C (688166) has a cash flow conversion efficiency ratio of 0.011x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥26.70 Million ≈ $3.91 Million USD) by net assets (CN¥2.35 Billion ≈ $344.34 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 688166 days of operational coverage to measure how many days the company can operate on defensive assets alone.

BrightGene Bio Medical Technology C - Cash Flow Conversion Efficiency Trend (2016–2024)

This chart illustrates how BrightGene Bio Medical Technology C's cash flow conversion efficiency has evolved over time, based on yearly financial data.

BrightGene Bio Medical Technology C Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of BrightGene Bio Medical Technology C ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Harley-Davidson Inc NYSE:HOG	-0.074x
SASA Polyester Sanayi AS IS:SASA	0.052x
Worthington Industries Inc NYSE:WOR	0.053x
Delek Logistics Partners LP NYSE:DKL	-8.454x
Siriuspoint Ltd NYSE:SPNT	-0.012x
Northeast Securities Co Ltd SHE:000686	0.322x
Genius Electronic Optical Co Ltd TW:3406	0.092x
Hand Enterprise Solutions Co SHE:300170	-0.011x

Annual Cash Flow Conversion Efficiency for BrightGene Bio Medical Technology C (2016–2024)

The table below shows the annual cash flow conversion efficiency of BrightGene Bio Medical Technology C from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see BrightGene Bio Medical Technology C (688166) market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CN¥2.44 Billion ≈ $356.66 Million	CN¥245.56 Million ≈ $35.93 Million	0.101x	+25.06%
2023-12-31	CN¥2.42 Billion ≈ $353.77 Million	CN¥194.77 Million ≈ $28.50 Million	0.081x	-41.98%
2022-12-31	CN¥2.24 Billion ≈ $328.03 Million	CN¥311.26 Million ≈ $45.55 Million	0.139x	+37.34%
2021-12-31	CN¥1.74 Billion ≈ $254.86 Million	CN¥176.08 Million ≈ $25.77 Million	0.101x	-6.82%
2020-12-31	CN¥1.43 Billion ≈ $209.63 Million	CN¥155.43 Million ≈ $22.74 Million	0.108x	+132.28%
2019-12-31	CN¥1.31 Billion ≈ $192.15 Million	CN¥61.33 Million ≈ $8.98 Million	0.047x	-43.58%
2018-12-31	CN¥772.85 Million ≈ $113.09 Million	CN¥63.99 Million ≈ $9.36 Million	0.083x	+3.25%
2017-12-31	CN¥446.02 Million ≈ $65.27 Million	CN¥35.77 Million ≈ $5.23 Million	0.080x	-40.63%
2016-12-31	CN¥220.15 Million ≈ $32.21 Million	CN¥29.73 Million ≈ $4.35 Million	0.135x	--

About BrightGene Bio Medical Technology C

SHG:688166 China Biotechnology

Market Cap

$2.68 Billion

CN¥18.28 Billion CNY

Market Cap Rank

#5372 Global

#1033 in China

Share Price

CN¥43.21

Change (1 day)

+7.01%

52-Week Range

CN¥40.25 - CN¥116.49

All Time High

CN¥116.49